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Abstract
Background: Since September 2005 the International Committee of Medical Journal Editors has required
that trials be registered in accordance with the World Health Organization (WHO) minimum dataset, in
order to be considered for publication. The objective is to evaluate registries' and individual trial records'
compliance with the 2006 version of the WHO minimum data set.
Methods: A retrospective evaluation of 21 online clinical trial registries (international, national, specialty,
pharmaceutical industry and local) from April 2005 to February 2007 and a cross-sectional evaluation of a
stratified random sample of 610 trial records from the 21 registries.
Results: Among 11 registries that provided guidelines for registration, the median compliance with the
WHO criteria were 14 out of 20 items (range 6 to 20). In the period April 2005–February 2007, six
registries increased their compliance by six data items, on average. None of the local registry websites
published guidelines on the trial data items required for registration. Slightly more than half (330/610;
54.1%, 95% CI 50.1% – 58.1%) of trial records completed the contact details criteria while 29.7% (181/610,
95% CI 26.1% – 33.5%) completed the key clinical and methodological data fields.
Conclusion: While the launch of the WHO minimum data set seemed to positively influence registries
with better standardisation of approaches, individual registry entries are largely incomplete. Initiatives to
ensure quality assurance of registries and trial data should be encouraged. Peer reviewers and editors
should scrutinise clinical trial registration records to ensure consistency with WHO's core content
requirements when considering trial-related publications.
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Registering clinical trials is a topical issue for the health
research community.[1] More than 30 years ago, the first
trials registry was initiated as a way to keep track of all tri-
als initiated and to make possible retrieval of information
about unpublished trials.[2] In the interim, several trials
registries have emerged, for many different purposes,
including recruiting patients to trials.[3]
To those performing systematic reviews, trials registries
provide an essential tool to assess completeness of the
information about all initiated trials addressing a given
research question, regardless of a trial's ultimate publica-
tion status. But to judge a trial's eligibility for inclusion in
a systematic review, the review team needs access to key
protocol information. A "minimum dataset" was initially
proposed in 1993[4] and has been updated since then.[5]
Despite a proliferation of small, specialized registries and
interest in a more comprehensive approach, there is cur-
rently no single worldwide registry that contains all ongo-
ing trials and is considered the acknowledged repository
of trial data. Coordinated efforts to assure global trial reg-
istration have lagged until recently, when a series of events
caught the attention of the broader medical community.
In 2004 the International Committee of Medical Journal
Editors (ICMJE), responding to reporting failures related
to harms from anti-depressants [6], strongly encouraged
the registration of trials. They issued a policy requiring tri-
als commencing participant enrollment after September
2005 to be registered in order to be considered for publi-
cation within their journals.[7] The ICMJE does not man-
date registration in any particular registry as long as it is
electronically searchable, freely accessible to the public,
open to all registrants, and managed by a non-profit
organization. However, the ICMJE requires that trials reg-
istration adhere to the 20-item minimum dataset defined
by the World Health Organization (WHO).[5] The World
Association of Medical Editors supported the ICMJE cam-
paign to register all clinical trials at their inception.[8] The
objective of this descriptive study is to evaluate whether
trial registries and individual trial records within the
selected trial registries complied with the WHO minimum
data set drafted in April 2005[5], issued in February
2006[9].
Methods
We defined a trial registry as a database of planned, ongo-
ing or completed trials, published or unpublished, con-
taining details of the trial's objectives, patient population,
sample size, and tested interventions.[4] This definition is
in agreement with the definition by the WHO.[10] An
official entry in the registry for a single trial is referred to
as a trial record.
Registry Compliance
In April 2005, we selected a convenience sample of 21 tri-
als registries for this study. These registries included inter-
national, national, disease specific, pharmaceutical industry,
and local registries. Details of the registries are presented in
Additional File 1. The registries were chosen because they
were widely known (except for the local registries),
online, active, freely accessible, and in English. To select
local registries we randomly sampled 10 institutions out
of 184 entities referring to limited geographic area (e.g.
UCSF University of California at San Francisco) and listed
in the 'hospitals and clinical research centres' subset of Tri-
alsCentral.[11]
For each registry in our sample, two reviewers independ-
ently abstracted whether key protocol items were present.
We defined key protocol items as the 20-item WHO min-
imum dataset drafted in April 2005 [5] and the subse-
quent version updated in February 2006 [9], and their
definitions for the appraisal checklist (Table 1). We
assessed how many of the WHO criteria were available for
registrants to complete ('registry compliance with WHO cri-
teria'). Two members of the team independently (LPM,
MN) continued to monitor trial registries' websites from
April 2005 to February 2007, collecting information
included on data fields, amendments and additions and
any mention of the ICMJE or WHO initiatives about reg-
istration. Disagreements were resolved by discussion
between the two study authors. We used a cohort design
to evaluate trial registry compliance over a prolonged
timeframe (number of WHO items included in each reg-
istry between April 2005 and February 2007).
Record Compliance
From each of the 21 selected registries we randomly sam-
pled a convenience preset number of trial records, to reach
a planned total of 600 records (final sample of 610 single
trial records). Samples varied according to registry storage.
No restrictions were placed on trial status, design or med-
ical area, although some registries had adopted inclusion
criteria. The trial record data collection was completed
between April and August 2005.
We assessed how commonly the WHO criteria were actu-
ally completed in single trial records ('record compliance').
When necessary, specific items were operationalized: for
example, the WHO criteria 'contact details' was divided
into 'name of contact person' and 'address', 'telephone',
'fax' or 'e-mail'. Key clinical and methodological details
were defined as the presence of condition, intervention,
study type, at least one outcome and key inclusion and
exclusion criteria. Although different registries and guide-
lines define the minimum data items with varying levels
of quality and detail, our operational definitions for con-
sidering an item "compliant" were inclusive. For example,Page 2 of 12
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Trials 2009, 10:56 http://www.trialsjournal.com/content/10/1/56Table 1: WHO minimal dataset: version issued in April 2005 (used as checklist in this study) [5] and revised version issued in February-
March 2006[9]
Item 2005 Revised Item 2006 Abridged Definition/Explanation*
1 Unique trial number Primary Registry and Trial Identification number Name of Primary Registry, and the unique ID number 
assigned by the Primary Registry to this trial.
2 Trial registration date Date of Registration in Primary Registry Date when trial was officially registered in the 
Primary Registry.
3 Secondary IDs Secondary identification number(s) Other identifying numbers and issuing authorities 
besides the Primary Registry, if any.
4 Funding source(s) Source(s) of Monetary or Material Support Major source(s) of monetary or material support for 
the trial (e.g., funding agency, foundation, company).
5 Primary sponsor Primary Sponsor The individual, organization, group or other legal 
person taking responsibility for securing the 
arrangements to initiate and/or manage a trial 
(including arrangements to ensure that the trial design 
meets appropriate standards and to ensure 
appropriate conduct and reporting).
6 Secondary sponsor(s) Secondary Sponsor(s) Additional individuals, organizations or other legal 
persons, if any, that have agreed with the primary 
sponsor to take on responsibilities of sponsorship.
7 Responsible contact person Contact for Public Queries Email address, telephone number, or postal address 
of the contact who will respond to general queries, 
including information about current recruitment 
status
8 Research contact person Contact for Scientific Queries Email address, telephone number, or postal address, 
and affiliation of the person to contact for scientific 
queries about the trial.
9 Title of the study (brief title) Public Title Title intended for the lay public in easily understood 
language.
10 Official scientific title of the study Scientific Title Scientific title of the trial as it appears in the protocol 
submitted for funding and ethical review. Include trial 
acronym if available.
11 Research ethics review Eliminated
Countries of Recruitment The countries from which participants will be, are 
intended to be, or have been recruited.
12 Condition Health Condition(s) or Problem(s) Studied Primary health condition(s) or problem(s) studied 
(e.g., depression, breast cancer, medication error).
13 Intervention(s) Intervention(s) Enter the specific name of the intervention(s) and the 
comparator/control(s) being studied. Use the 
International Non-Proprietary Name if possible. If the 
intervention consists of several separate treatments, 
list them all. For each intervention, describe other 
intervention details as applicable (dose, duration, 
mode of administration, etc).
14 Key inclusion and exclusion criteria Key Inclusion and exclusion criteria Inclusion and exclusion criteria for participant 
selection, including age and sex.Page 3 of 12
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assigned into either cyclophosphamide (0.5 to 1 g/m2) or
methylprednisolone (1 g/m2) infusion; both treatments
will be administered every four weeks during one year"
would have been considered completed in the trial record
for the purpose of this study, whereas an intervention
reported as "adjuvant treatment" without other details
would have been considered incomplete (See Additional
file 2 for the operational definitions we adopted). Dupli-
cate data extraction was undertaken for the first 50 trial
records and inter-rater reliability was assessed with k sta-
tistic (0.80–1 k statistic values for the majority of fields).
Subsequent data extraction was undertaken by a single
rater. We calculated 95% confidence intervals using bino-
mial approximation.
The evaluation of the 610 individual trial records was
done at a single point in time (April-August 2005) and
thus is a cross-sectional study.
Results are presented as percentage compliance with
WHO items. The percentages are expressed with 95% con-
fidence intervals in parentheses. Percentage of registry not
compliant items for 2005 and 2006 were calculated as
independent data and the difference between the two per-
centages were evaluated by Chi-Square test.
Results
Registry Compliance
Table 2 lists registries and compliance by item with the
WHO minimum data set. None of the local registry web-
sites published definitions of the trial information (sub-
mission fields) required for registration or mentioned the
recent initiatives of the ICMJE or WHO; two local regis-
tries did not include any trial records.
During the period April 2005 to February 2007, six regis-
tries increased their compliance with WHO criteria by 6
data items, on average, ameliorating their compliance
from 10 to 16 items. Two international (ClinicalTrials.gov
and ISRCTN) and one national registry (ACTR) modified
their content submission fields to become fully compliant
with WHO standards during our data collection period.
Two pharmaceutical industry registries (Novartis and
ClinicalStudyResults) that completely lacked registration
criteria and definitions in April 2005 modified their struc-
ture, increasing the number of items offered to 6 and 14
respectively. The Roche registry rose from 9 to 16 items.
The RehabTrials.org registry stopped being accessible in
2006. In the subgroup of registries providing guidelines
for registration (11 registries), by February 2007, median
compliance with the WHO criteria was 14 out of 20 items
(range 6 to 20). From 2005 to 2006 the number of registry
not compliant items decreased significantly from 46.4%
(39.6–53.2) to 30.0% (24.0–36.5) (p = 0.0039).
15 Study type Study Type A single arm trial is one in which all participants are 
given the same intervention. A trial is "randomized" if 
participants are assigned to intervention groups using 
a method based on chance.
16 Anticipated trial start date Date of First Enrollment Anticipated or actual date of enrollment of the first 
participant.
17 Target sample size Target Sample Size Number of participants that this trial plans to enroll.
18 Recruitment status Recruitment Status Recruitment status of this trial (e.g., pending, active, 
temporary halt, closed).
19 Primary outcome Primary Outcome(s) Outcomes are events, variables, or experiences that 
are measured because it is believed that they may be 
influenced by the intervention. The Primary Outcome 
should be the outcome used in sample size 
calculations, or the main outcome(s) used to 
determine the effects of the intervention(s). Enter the 
names of all primary outcomes in the trial as well as 
the pre-specified timepoint(s) of primary interest.
20 Key secondary outcomes Key Secondary Outcomes Secondary outcomes are events, variables, or 
experiences that are of secondary interest or that are 
measured at timepoints of secondary interest.
* From the final version released in February 2006
Table 1: WHO minimal dataset: version issued in April 2005 (used as checklist in this study) [5] and revised version issued in February-
March 2006[9] (Continued)Page 4 of 12
(page number not for citation purposes)
Trials 2009, 10:56 http://www.trialsjournal.com/content/10/1/56Table 2: Types of trial registries and compliance with WHO criteria at the end of data collection period (February 2007).
Registries
International National Specialty Pharma Local Total out of 11 
registries 
(excluding locals)
Criteria requested ISCRTN CT ACTR UK NRR PDQ STD RT† R GSK N CSR
Details not presented by 
registries
x
Details available
Unique trial number x x x x x x x x x 9
Trial registration date x x x x 4
Secondary Ids x x x x x x 6
Funding source(s) x x x x x x x x x x 10
Primary sponsor x x x x x x x x 8
Secondary sponsor(s) x x x x X x 6
Responsible contact 
person
x x x PNR x 5
Research contact person x x x x x x x x 8
Title of the study 
(brief title)
x x x x x x x x 8
Official scientific title of 
the study
x x x x x x x x x x 10
Research ethics review* x PNR x MC PNR 4
Countries of recruitment 
(replaced ethics review, 
May 2006)*
x x x x x x 6
Condition x x x x x x x x x x 10
Intervention(s) x x x x x x x x x 9
Key inclusion and 
exclusion criteria
x x x x x x x x 8
Study type x x x x x x x x 8
Anticipated trial start date x x x x x x x x x 9
Target sample size x x x x x x x 7
Recruitment status x x x x x x x 7
Primary outcome x x x x x x x x x 9
Key secondary outcomes x x x x x x x 7
Total out of 20 criteria‡ 20 20 20 13 16 14 5 16 10 6 14Page 5 of 12
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Table 3 lists the percentages of compliant records relative
to registries. The final sample of 610 trial records covered
different years (range: 1981 to 2005). However the major-
ity of trials were recently registered (<1999 n = 77 (13%
out of 610); 2004–2000 n = 246 (40% out of 610); 2005
n = 156 (26% out of 610)). In 131 records the registration
date was not available. Overall, 330 trial records, 54.1%
(50.1% – 58.1), completed the contact details criteria.
Trial records in national registries adhered more often
with this requirement (compliance 99%) while those in
drug company registries never reported it (Figure 1). 181
records, 29.7% (26.1 – 33.5), provided complete infor-
mation about key aspects of trial design (target condition,
intervention, study type, at least one outcome and key
inclusion and exclusion criteria; Figure 2). Among these
five key methodological data fields compliance varied
across items from 40.5% (36.6 – 44.5) for primary out-
come measures to 75.2% (71.6 – 78.6) for target condi-
tion. 'Research ethics review' (6.9% (5.0% – 9.2)),
'responsible contact person' (8.2% (6.1 – 10.7)) and 'sec-
ondary outcomes' (21.6% (18.4% – 25.1)) had lower
compliance rates.
Discussion
Summary of key findings
As of February 2007, the compliance of information in
trial registries is unsatisfactory despite the emerging con-
sensus that the availability of such information is ethically
and scientifically essential.[12] We found that in August
2005, only 54% of trial records provided adequate contact
information and less than 30% contained the complete
information necessary to provide a general picture of trial
objectives, such as outcome measures and details of the
intervention. The launch of the WHO minimum dataset
and its enforcement by the ICMJE seemed to positively
influence registries: 6 out of 11 increased their compliance
by the time of the ICMJE requirement. Some of the WHO
criteria seemed to be easily adopted by registries, while
others were less so: compliance was variable among regis-
tries and there were inconsistencies between registry-
offered fields and record compliance (i.e., many registries
Mentions WHO 2005/
2006
x x x x - x - - - - -
Mentions ICJME 2004/
2005
x x x x - - - - - - -
X = items present when data collection begun; X = items added during study period; ‡Total criteria considering the field 'Countries of recruitment'.
MC = only for multi-centre trials; PNR = provided not reported.
Abbreviation: ISRCTN, Current Controlled Trials; CT, ClinicalTrials.gov; ACTR, Australian Clinical Trials Registry; UK NRR, UK National 
Research Register; PDQ, US National Cancer Institute; STD, Stroke Trials Directory; RT, Rehabilitation Trials († access to web site withdrawn in 
2006); R, Roche; GSK, GlaxoSmithKline; N, Novartis; CSR, ClinicalStudyResults.
Table 2: Types of trial registries and compliance with WHO criteria at the end of data collection period (February 2007). (Continued)
Contact detailsFigure 1
Contact details. Percentage (95% confidence interval) of trial records reporting minimum contact details (defined as the 
presence of name of contact person and one additional item: address, telephone, fax or e-mail) by type of registry.
0
20
40
60
80
100
International
(n=200)
National (n=100) Specialty (n=99) Pharma (n=121) Local (n=90)
Type of registry
%
 
Co
m
pl
et
io
n
 
(95
%
 
CI
)Page 6 of 12
(page number not for citation purposes)
Trials 2009, 10:56 http://www.trialsjournal.com/content/10/1/56failed to offer all 20 WHO data items for completion, and
registrants failed to comply with many of the data items
that were offered).
Strengths and weaknesses
Our assessment was limited to a sample of 21 registries to
reflect different types of registries.[13] Our sample of
records can be criticised in some respects. Although we
chose the registries to reflect diversity based upon a priori
defined important information (e.g., target health profes-
sionals or patients, profit or no-profit aims, etc), and with-
out prior knowledge of what we would find, the selection
was largely of registries published in English. We consid-
ered including registries from Spain and Italy which have
country-wide mandatory trial registration [14,15] but
their registries did not meet our inclusion criteria of being
in the public domain. In Italy only funding agencies and
ethics committees have unrestricted access. In Spain the
online version of their national registry is still under con-
struction. It is possible that these registries differ from oth-
ers in terms of the amount and quality of information
collected and this may limit the generalisability of this
study. Our results for a sample of trials registries in 2005–
2007 are a snapshot from what has become a rapidly
evolving field. For example, in 2005–2007 the WHO for-
mally established the International Clinical Trials Registry
Platform (ICTRP) to standardise the scope and content of
trial registration.[16] The WHO finalized the criteria to
build a global network of qualified registries, adopting a
hierarchical structure (primary and partner registries) and
creating a web site that enables users to search a central
database that contains the trial registration data sets pro-
vided by primary registries.[17] Triggered by the ICMJE
and WHO initiatives, trial registration has become very
active. Thus, ClinicalTrials.gov increased from a routine
weekly registration of 30 new trials to 220 new trials [18]
and changed its registration requirements http://prs
info.clinicaltrials.gov.[19] ISRCTN's trial records
expanded from 2 705 to 6 449, and transferred its owner-
ship to a not-for-profit organization to comply with the
ICMJE requirement that registries be non-profit adopting
a new URL http://isrctn.org.[20] Since 2007, ISRCTN has
required an administrative charge (£132) to registry new
trials, while ClinicalTrials.gov maintains a free of charge
policy. The Australian Clinical Trials Registry (ACTR) was
established in April 2005 by merging old registries into a
new highly standardised version incorporating the com-
plete WHO minimum dataset.[21] At the time of our
study, the Lilly website only linked to its records in Clini-
calTrials.gov but has since launched its own registry with
information about recruiting and non-recruiting trials,
while also providing identification numbers.[22]
Another element of change is related to our assessment
tool: we used the draft April 2005 WHO minimum dataset
to assess the trials registered in our study, although the
finalised version released in February 2006 was somewhat
different (research ethics review item was removed and
Countries of recruitment was added).[9] The draft and final
dataset versions are shown in Table 1 (definitions/expla-
nations are from the final version). Neither version of the
WHO dataset was available for use as a benchmark by reg-
istries and registrants before April 2005. Our findings
highlight the variation in registry and record compliance
Clinical and methodological detailsFigure 2
Clinical and methodological details. Percentage (95% confidence interval) of trial records reporting clinical and methodo-
logical details (defined as the presence of condition, intervention, study type, at least one outcome and key inclusion and exclu-
sion criteria) by type of registry.
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Registries (number of records)
International National Specialty
Criteria requested ISCRTN 
(n = 100)
CT 
(n = 100)
ACTR (n = 50) UK NRR 
(n = 50)
PDQ 
(n = 33)
STD 
(n = 33)
RT 
(n = 33)
R 
(n = 8)
Unique trial number 100 100 100 100 0 0 0 100
Trial registration date 100 100 100 100 100 100 100 100
Secondary Ids 100 91 16 4 100 0 0 0
Funding source(s) 100 100 96 76 66.7 69.7 90 100
Primary sponsor 100 100 90 92 66.7 69.7 90.9 100
Secondary sponsor
(s)
14 10 38 0 0 6.1 6.1 0
Responsible contact person 0 0 100 0 0 0 0 0
Research contact person 95 20 100 98 93.9 63.6 30.3 0
Title of the study (brief title) 98 18 66 0 0 60.6 0 0
Official scientific title of the study 83 95 100 94 97 69.7 84.9 100
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(5.0 to 9.2)
84.9 100 95.8 100 83.8 22.2 75.2 
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42.4 0 100 0 64.9 17.8 58.4 
(54.3 to 62.3)
0 100 97.2 50 64.9 28.9 58.5 
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33.3 0 94.4 0 64.9 45.6 61.3 
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39.4 0 80.6 0 64.9 0 55.2 
(51.2 to 59.2)
12.1 100 0 0 54.1 7.8 50.0 
(46.0 to 54.0)
18.2 0 83.3 0 64.9 2.2 40.5 
(36.6 to 44.5)
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Research ethics review 1 0 78 0 3 0
Condition 70 85 92 66 97 100
Intervention(s) 56 68 74 24 75.8 97
Key inclusion and exclusion criteria 23 97 100 44 18.2 87.9
Study type 43 74 98 58 9.1 97
Anticipated trial start date 8 65 100 100 0 39.4
Target sample size 40 83 100 24 72.7 100
Recruitment status 3 99 100 100 93.9 100
Primary outcome 7 48 100 34 0 100
Key secondary outcomes 6 10 58 6 6.1 54.6
Note: In CT, PDQ and STD 'Funding source(s)' and 'Primary sponsor' are not distinct. By default contact person without spec
Abbreviation: ISRCTN, Current Controlled Trials; CT, ClinicalTrials.gov; ACTR, Australian Clinical Trials Registry; UK NRR, 
Stroke Trials Directory; RT, Rehabilitation Trials; R, Roche; GSK, GlaxoSmithKline; N, Novartis; CSR, ClinicalStudyResults.
Table 3: Percentage of compliance of trial records according to WHO criteria by trial registry. (Continued)
Trials 2009, 10:56 http://www.trialsjournal.com/content/10/1/56with the 2005 WHO criteria up to February 2007. It
should be also stressed that registry and record compli-
ance are not independent since registrants can only pro-
vide the information requested, and therefore the
variation in registry compliance will constrain record
compliance. As with previous studies, we could not evalu-
ate the actual proportion of trials registered among all tri-
als conducted over the time period examined: this could
be achieved only assessing the number of trials launched
at the source point (e.g., funding agencies, industry, ethics
committees, regulators) and it is out of the scope of the
present work.
Our study in context
Our results partially overlap with the results reported by
Zarin et al. who surveyed record completion on Clinical-
Trials.gov between May and October 2005.[23] Zarin
assessed completeness of Intervention name (compliance
rates at 100% and 90% for non-industry and industry
records, respectively) and Primary outcome (compliance
rate available only for industry records, 76%). We found
lower compliance for Intervention name (68%), though
this difference could be because we examined registries
over a different time interval. As Zarin et al. showed, many
records changed their completion of registration around
the time of ICJME deadline: it is possible that investigators
were motivated to update the recent records over the older
ones or that registries' editors started to scrutinise trial
records with more stringent policies.[18] If true, this could
also explain the lower compliance rate we found for Pri-
mary outcome compared to Zarin et al. Completion rate
also depends on the operational definition adopted by
assessors. The definition used by Zarin et al. is less strin-
gent compared to the one we adopted.
An interesting result of our study is that industry registries
appear to satisfy WHO minimal dataset in terms of meth-
odological details more completely than non-industry
registries. This result seems to contrast with the pharma-
ceutical industry's concern over the disclosure of the five
methodological items.[24] This finding could be due to
trials listed on company registries are for 'approved drugs'
and the information is no longer considered to be com-
mercially sensitive. Another possibility is that the different
drug companies, while having a common overall posi-
tion, ultimately adopt heterogeneous policies on disclos-
ing their data items. Pharmaceutical company registries
did not include details in their registries for a contact per-
sons for each trial, although they did include an e-mail
address for additional information about trials. This was
not considered as meeting the WHO criterion, however, as
accountability appeared too vague if a contact name was
not provided. These results have been confirmed by
another study which analysed the proportion of trial
records listing complete contact information of Canadian
investigators in a sample of records in ISRCTN and Clini-
calTrials.gov and found largely incomplete contact infor-
mation in industry funded trials.[25]
Conclusion
Implications for systematic reviewers
As part of their broad search to identify potentially eligible
data systematic reviewers should include trial registries for
ongoing trials, particularly in situations where there is
great uncertainty about the efficacy of an intervention and
it is possible that new trial data may influence the sum-
mary judgment of the review. Our findings revealed that
registries often do not contain meaningful information on
many key methodological data fields and thus at this time
cannot be used reliably as referent information sources to
describe included studies in systematic reviews. Details of
research contact persons, when present, can be used to
address questions about methodological aspects of a trial
or unpublished data.
Implications for trial registration
In the move towards global trial registration, there is room
for better standardisation of approaches and better report-
ing of registration data items. This effort is in keeping with
other global efforts to improve the reporting of ran-
domised trials, such as the CONSORT Statement.[26] The
WHO is developing criteria for internationally acceptable
trial registries, and has established a working group of trial
registries to develop better approaches to data entry vali-
dation and other aspects of quality assurance.[27] Given
the variability in registry compliance and record com-
pleteness, editors and peer reviewers of medical journals
should scrutinise trial registration records to ensure con-
sistency with WHO's minimum dataset when considering
trial-related publications and should report the trial iden-
tification numbers, including those assigned by WHO.
Implications for research
As registries adopt the WHO minimum dataset, there is a
need to assess the evolution of registries and records over
time, and whether the 20 WHO criteria are sufficient to
judge the scientific conduct of trials or should be
expanded. Further research is also needed to determine
whether early trial registration increases informed patient
recruitment and improves quality and completeness of
subsequent publications: the impetus for clinical trial reg-
istration stems from the added value of including all clin-
ical trials, not just published ones, within systematic
reviews.[6] As such, there is a need to prospectively mon-
itor protocol amendments and the accessibility of unpub-
lished clinical trial data. Including primary outcome
information within a registry will also enable us to evalu-
ate whether the disturbingly high frequency of outcome
reporting bias declines.[28,29] Following from these
ideas, trial registries will be most useful if they increase thePage 10 of 12
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In other words, the real test for trial registries is whether
they facilitate making the results of unpublished trials,
and unpublished results of published trials, available to
the public. whether through trial registries or dedicated
results repositories or databases.[30] The United States
FDA Amendments Act 2007 (U.S. Public Law 110-85),
which is the world's first legislative requirement for the
public reporting of trial results, is an important step in this
direction. Simply registering trials is not going to solve the
problem, but it is a necessary first step to enable identifi-
cation of all trials and the subsequent tracking of their
results.
Clinical trial registration was advocated more than thirty
years ago[2], and important progress has recently been
made. We have a scientific, ethical and moral obligation
to clinical trial participants to ensure that clinical trial reg-
istries are created with and adhere to the highest possible
standards.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LM, AL and JMG conceived the study concept. LM, IM,
MN, AL, JMG and AWC conceived the study protocol. LM,
IM and MN were involved in the acquisition of data. LM,
IM, MN and AC were involved in the analysis of data. LM,
IM, MN, AL and JMG were involved in drafting of the
manuscript. All authors were involved in the interpreta-
tion and critical revision of the manuscript for important
intellectual content.
Additional material
Acknowledgements
We thank Bushra Chaudry, research assistant, Clinical Epidemiology Pro-
gram, Ottawa Health Research Institute, for helping us extracting trial 
records' information. We are grateful to Drummond Rennie for his valua-
ble comments. Funding/Support: Jeremy Grimshaw holds a Canada 
Research Chair in Health Knowledge Transfer and Uptake. David Moher 
holds a University of Ottawa Research Chair.
References
1. Rennie D: Trial registration: a great idea switches from
ignored to irresistible.  Jama 2004, 292(11):1359-1362.
2. Levine J, Guy W, Cleary P: Therapeutic trials of psychopharma-
cologic agents: 1968–1972.  Armonk, NY: Futura Publishing Co;
1974. 
3. Dickersin K, Rennie D: Registering clinical trials.  Jama 2003,
290(4):516-523.
4. International collaborative group on clinical trial registries: Position
paper and consensus recommendations on clinical trial reg-
istries. Ad Hoc Working Party of the International Collabo-
rative Group on Clinical Trials Registries.  Clin Trials Metaanal
1993, 28(4–5):255-266.
5. Deangelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R,
Kotzin S, Laine C, Marusic A, Overbeke AJ, et al.: Is this clinical trial
fully registered? A statement from the International Com-
mittee of Medical Journal Editors.  Jama 2005,
293(23):2927-2929.
6. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Bod-
dington E: Selective serotonin reuptake inhibitors in child-
hood depression: systematic review of published versus
unpublished data.  Lancet 2004, 363(9418):1341-1345.
7. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R,
Kotzin S, Laine C, Marusic A, Overbeke AJ, et al.: Clinical trial reg-
istration: a statement from the International Committee of
Medical Journal Editors.  Jama 2004, 292(11):1363-1364.
8. World Association of Medical Editors (WAME) Editorial Pol-
icy Committee. The Registration of Clinical Trials   [http://
www.wame.org/resources/policies#trialreg]
9. Sim I, Chan AW, Gulmezoglu AM, Evans T, Pang T: Clinical trial
registration: transparency is the watchword.  Lancet 2006,
367(9523):1631-1633.
10. World Health Organization (2009). International Clinical
Trials Registry Platform (ICTRP): glossary   [http://
www.who.int/ictrp/glossary/en/index.html]
11. TrialsCentral   [http://www.trialscentral.org]
12. Krleza-Jeric K, Chan A-W, Dickersin K, Sim I, Grimshaw J, Gluud C,
for the Ottawa G: Principles for international registration of
protocol information and results from human trials of health
related interventions: Ottawa statement (part 1).  BMJ 2005,
330(7497):956-958.
13. Shadish W, Cook T, Campbell D: Generalized causal inference:
a grounded theory.  In Experimental and quasi-experimental design for
generalized causal inference Boston: Houghton Mifflin Company;
2002:341-373. 
14. REAL DECRETO 561/de 16 de abril, por el que se estabecen
los requisitos para la realiciacion de ensayos clinicos con
medicamentos.  .
15. Legislative decree no. 211 of 24 June 2003   [https://oss-sper-
clin.agenziafarmaco.it/normativa/decreto_24062003_inglese.pdf]
16. Gulmezoglu AM, Pang T, Horton R, Dickersin K: WHO facilitates
international collaboration in setting standards for clinical
trial registration.  Lancet 2005, 365(9474):1829-1831.
17. World Health Organization (WHO). International Clinical
Trials Registry Platform Search Portal   [http://www.who.int/
ictrp/search/en/]
18. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DA: Issues
in the registration of clinical trials.  JAMA 2007,
297(19):2112-2120.
19. ClinicalTrials.gov: Protocol Registration System Informa-
tion   [http://prsinfo.clinicaltrials.gov]
20. Current Controlled Trials Ltd: ISRCTN Register   [http://
www.isrctn.com/]
21. Australian Clinical Trials Registry (ACTR)   [http://
www.actr.org.au]
22. Eli Lilly and Company Clinical Trial Registry   [http://www.lil
lytrials.com/]
23. Zarin DA, Tse T, Ide NC: Trial Registration at ClinicalTrials.gov
between May and October 2005.  N Engl J Med 2005,
353(26):2779-2787.
Additional file 1
Appendix 1. URLs and type of trials registries. Accessed November 2005 
and monitored until February 2007.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1745-
6215-10-56-S1.doc]
Additional file 2
Appendix 2. Operational definitions adopted for the purposes of this 
study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1745-
6215-10-56-S2.doc]Page 11 of 12
(page number not for citation purposes)
Trials 2009, 10:56 http://www.trialsjournal.com/content/10/1/56Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
24. Krleza-Jeric K: Clinical trial registration: the differing views of
industry, the WHO, and the Ottawa Group.  PLoS Med 2005,
2(11):e378.
25. Sekeres M, Gold JL, Chan AW, Lexchin J, Moher D, Van Laethem ML,
Maskalyk J, Ferris L, Taback N, Rochon PA: Poor reporting of sci-
entific leadership information in clinical trial registers.  PLoS
ONE 2008, 3(2):e1610.
26. Moher D, Schulz KF, Altman DG: The CONSORT statement:
revised recommendations for improving the quality of
reports of parallel-group randomized trials.  Ann Intern Med
2001, 134(8):657-662.
27. World Health Organization: Information for Register
Administrators   [http://www.who.int/ictrp/en]
28. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG:
Empirical evidence for selective reporting of outcomes in
randomized trials: comparison of protocols to published
articles.  Jama 2004, 291(20):2457-2465.
29. Chan AW, Krleza-Jeric K, Schmid I, Altman DG: Outcome report-
ing bias in randomized trials funded by the Canadian Insti-
tutes of Health Research.  Cmaj 2004, 171(7):735-740.
30. Sim I, Detmer DE: Beyond trial registration: a global trial bank
for clinical trial reporting.  PLoS Med 2005, 2(11):e365.Page 12 of 12
(page number not for citation purposes)
